As part of the agreement, Dvir's lab and Bayer will aim to test new cardiology medication for toxicity and efficacy.

Researchers at Tel Aviv University say they have developed technology to engineer any type of tissue for transplantation from patients' own biomaterials and cells, greatly reducing the risk of rejection.